Search

Displaying results 4741 - 4750 of 10000 in total
  1. Target

    C-type lectin domain family 7 member A

    go.drugbank.com/bio_entities/BE0019143
    TargetHumans

    Lectin that functions as a pattern recognizing receptor (PRR) specific for beta-1,3-linked and beta-1,6-linked glucans, which constitute cell wall constituents from pathogenic bacteria and fungi (PubMed

    Synonyms: Beta-glucan receptor
  2. Drug

    QS-21

    go.drugbank.com/drugs/DB05400
    Investigational

    QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment … It is the leading member of the Stimulon family of adjuvants. As a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics.

  3. Drug

    Fenoxaprop-ethyl

    go.drugbank.com/drugs/DB05252
    Experimental

    Fenoxaprop-ethyl has been investigated to treat chronic angina, the chest pain that occurs from inadequate blood flow to the coronary arteries around the heart. … Fenoxaprop-ethyl (organic nitrate combined with L-arginine), is an oral proprietary nitrate therapeutic shown to induce coronary vasodilation while overcoming the significant problem of drug tolerance.

  4. Drug

    Oxiconazole

    go.drugbank.com/drugs/DB00239
    Approved

    It is marketed under the brand names Oxistat and Oxistat, and is used in the treatment of various skin infections such as athlete's foot, jock itch and ringworm.

  5. Drug

    GnRH pharmaccine

    go.drugbank.com/drugs/DB05815
    Experimental

    The pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation … The GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle".

  6. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. … Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4).

    Categories: Increased T Lymphocyte Activation
  7. Drug

    AT1022

    go.drugbank.com/drugs/DB04995
    Experimental

    AT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect. … AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain.

  8. Drug

    Epicept NP-1

    go.drugbank.com/drugs/DB05492
    Investigational

    The peripheral nervous system includes nerves that run from the brain and spinal cord to the rest of the body. … Peripheral neuropathies are medical conditions caused by damage to the nerves in the peripheral nervous system.

  9. Drug

    Camptothecin

    go.drugbank.com/drugs/DB04690
    Investigational

    Camptothecin is an alkaloid isolated from the stem wood of the Chinese tree, <i>Camptotheca acuminata</i>. This compound selectively inhibits the nuclear enzyme DNA topoisomerase, type I.

  10. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy. … This study was designed to evaluate whether avosentan influences the pharmacokinetics of steroid oral contraceptives.